BioTech Scout

Discover the most promising early-stage companies in life sciences, scouted by BioPharmaTrend. Follow company news and important business events.

back to Directory

Cellectis

Cellectis logo

Founded
2006
Patents
53
Clinical Trials
5
Publications
88

Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its proprietary gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells